BioNut researchers awarded 45 million SEK from the Swedish cancer society

Extended support for cancer research

Apart from the support for specific projects mentioned in the list below, we wish to just highlight two of the researchers at BioNut who received extended support for their cancer research for the years 2021-2023. That is Andreas Lennartsson, who received another 3 million sek and Martin Bergö, who received another 9 million sek:

Personalized epigenetic combination therapies for AML

"We will investigate whether personalized epigenetic manipulation can enhance the sensitivity for downstream drug treatment of acute myeloid leukemia", says Andreas Lennartsson. He explains further that the aim of their research is to find new drug combinations that will improve the treatment efficiency and prognosis of the patients. "This is a high risk, but high gain project that we couldn’t perform without the extra support from Cancerfonden", he continues. 

Defining the role of immune system and CCL28 in lung cancer progression and metastasis

"We recently made two surprising findings in another project, which led to the hypotheses that one or more immune cell is required for the development of metastasis and that lung cancer cells are driven by an autocrine CCL28-CCR3 loop", says Martin Bergö. The project is a high-risk project where they, together with new collaborators in Europe, will test these hypotheses. They hope to increase the fundamental knowledge of mechanisms underlying lung cancer metastasis and potentially find new strategies to stop these most lethal of cancer-related processes.